MODAFINIL by Novartis is 12. Approved for excessive sleepiness, wakefulness in adult patients with excessive sleepiness associated with narcolepsy, obstructive sleep apnea (osa) and 1 more indications.
Drug data last refreshed 4w ago
12.1 Mechanism of Action The mechanism(s) through which modafinil promotes wakefulness is unknown. Modafinil has wake-promoting actions similar to sympathomimetic agents including amphetamine and methylphenidate, although the pharmacologic profile is not identical to that of the sympathomimetic…
Worked on MODAFINIL at Novartis? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
A Clinical Study of MK-6552 and Modafinil in Healthy Men (MK-6552-005)
Effect of Multiple Doses of Modafinil on the Pharmacokinetics of Single Dose Lorlatinib in Healthy Participants
Effect Of Modafinil And Pioglitazone On The Pharmacokinetics Of Palbociclib (PD-0332991)
The Treatment of Insomnia Comorbid With Sleep Disordered Breathing Using Armodafinil and/or Cognitive Behavioral Therapy for Insomnia
Armodafinil in Reducing Cancer-Related Fatigue in Patients With High Grade Glioma